Panacea Biotec is expanding its partnership with Apotex to launch a copycat version of Eli Lilly’s Effient in the US, part of an alliance-building strategy with global players that the Indian firm hopes can help pull it out of an earnings tailspin.
Indian drug-maker Panacea Biotec Ltd. has won tentative US FDA approval for its first-to-file ANDA for a generic version of Eli Lilly & Co.’s blood-thinner Effient (prasugrel). Now, to get the copycat prasugrel to the US market, Panacea is expanding an alliance with Apotex Inc., the largest Canadian-owned pharmaceutical company.
Under the agreement, the closely held Canadian firm will handle US sales and distribution of prasugrel in 5mg-to-10mg doses while...
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
